Implication of China 2012 NEDL. Presented by: Li Xingwei Yong Hueyling
|
|
- Sheena Holmes
- 7 years ago
- Views:
Transcription
1 Implication of China 2012 NEDL to MNC pharma players Presented by: Li Xingwei Yong Hueyling
2 Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012 NEDL on MNCs Counter actions by MNCs and the impact on MR providers 抛 砖 引 玉 Cast a brick to attract jade -- offer a few commonplace remarks by way of introduction so that others may come up with valuable opinion 2
3 China National Essential Drug List (NEDL) Policy The first version of China National Essential Drug List (NEDL) was introduced in 2009, and is to be renewed every 3-4 years. In March 2013 China MOH released the second version of NEDL (more commonly known as 2012 NEDL) NEDL aims to, as well as to ensure access to essential drugs reduce government s spending on healthcare over time General requirements of NEDL Key issues Reasonable pricing Affordability Fulfilling basic healthcare needs Suitable formulation and dosage Accessibility Assurance of drug supply 3
4 Affordability Accessibility China National Essential Drug List (NEDL) Policy To reduce government s healthcare expenditure, drug manufacturers are requested to offer a sharp price cut before they are allowed to bid for NEDL drug tendering Besides that, drug s price is the most important factor in drug choice during tender process, and in some provinces, it is the ONLY consideration Average Price cut after NEDL tender 53% 39% 26% That said Anhui (2010) Shanghai (2011) Beijing (2012) In recent tenders, product quality has been included as one of the evaluation criteria and price is slightly de-prioritized. This change alleviates the excessive competition on price alone and helps MNC players, who are perceived to offer better quality products. 4
5 Affordability Accessibility China National Essential Drug List (NEDL) Policy New revisions in 2012 NEDL: Increased coverage on TAs/ molecules, and Greater enforcement, varies across hospitals of different sizes 2009 NEDL 2012 NEDL Notable changes Total number of molecules Therapeutic focus Basic needs Additional needs Added oncology, blood, pediatric drugs Required revenue ratio from NEDL drugs Small hospitals (Class 1 and primary healthcare centers, e.g. CHCs, Township healthcare center, etc.) 100% 100% NA Medium hospitals (Class 2 hospitals) 25-35% 40-50% +15% Big hospitals (Class 3 hospitals) 15-25% 25-30% +7.5% 5
6 Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012 NEDL on MNCs Counter actions by MNCs and the impact on MR providers 6
7 Overview of China hospital system by hospital level Big and medium hospitals generate 75% of total hospital revenues on medication, and manage approx. one third of patients making them the focal point of MNC pharmaceutical companies 100% Contribution from hospitals of different sizes 10% 2% 17% 80% 19% 45% Big hospitals 60% 40% 20% 88% 65% 30% 25% Medium hospitals Small hospitals 0% # of Institution Patient load Hospital revenue on medication 67, billion billion USD Source: MOH year book 2012, IMS China hospital pharmacy audit data
8 Overview of China hospital system by city tier In tier 1-2 cities, medication revenues are mainly generated from big/medium hospitals; to the contrary, small/ medium hospitals play dominant role in lower tier cities. Therefore, the impact from 2012 NEDL will be more felt in lower tier cities % of revenue Contribution to medication revenue by hospital type No. of cities Hospital revenues on medication Tier 1-2 cities Tier 1: Beijing, Shanghai, etc. Tier 2: Nanjing, Shenyang, etc. 18% 24% 58% billion USD Tier 3-4 cities Tier 3: Fuzhou, Nanchang, etc. Tier 4: Yangzhou, Baotou, etc. Tier 5 and below cities Tier 5: Huangshi, Xianyang, Xingtai, etc. 22% 41% 31% 37% Source: MOH year book 2012, IMS China hospital pharmacy audit data % 22% Small hospitals Medium hospitals Big hospitals 101 > billion USD 24.0 billion USD 8
9 MNCs current focus Currently, MNCs business is highly focused on high tier cities and big hospitals MNCs contribution to total pharma market sales (hospital channel only) 100% Sales contribution by hospitals type (SH & BJ) Local MNC 80% 60% 40% 45% 26% 63% Big hospitals Medium hospitals Small hospitals Market size/ USD billion 40% Tier 1 cities 31% Tier 2 cities 24% 22% Tier 3 cities Tier 4 cities < 10% Tier 5 & below (Est.) % 0% 29% Total market 20% 17% MNCs Source: IMS CHPA/CHC database 9
10 MNCs business vs. NEDL direction Hence MNC pharma companies and NEDL are growing in opposite directions on: Hospital coverage Focus on cities Impact of NEDL Big hospitals and High tier cities Greater Greater Small hospitals and Low tier cities Presence of MNC pharma 10
11 Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012 NEDL on MNCs Counter actions by MNCs and the impact on MR providers 11
12 Change in tendering policy In the past, most MNCs were able to choose Non-NEDL market, and give up NEDL market in order to maintain its premium pricing. However, going forward, giving up NEDL market will mean losing total China market. As the latest policy demands all NEDL enlisted drugs to enter hospitals via NEDL tender ONLY, this means PRICE CUT is inevitable Past Future Non-NEDL tendering: No price cut Can t enjoy NEDL benefit NEDL tendering: Price cut Enjoy NEDL benefit NEDL drugs NEDL tendering: used as NEDL drug 12
13 2012 NEDL s impact on MNCs business Compared to 2009 NEDL, the latest NEDL will have greater impact on MNCs as number of molecules and products involved had doubled. Influence of 2009 NEDL vs NEDL to MNCs revenues ~4X ~2X 3,732 mil. USD ~2X mil. USD No. of moleculars involving MNCs No. of MNC products invovled Total revenue (hospital channel) 13
14 2012 NEDL s impact on MNCs And several leading companies will be greatly influenced by the new NEDL Company % of NEDL drugs in total company revenues Change Bayer 29% 51% +22% Sanofi 2% 49% +47% Baxter 10% 45% +35% BMS 21% 38% +17% AstraZeneca 28% 30% +2% Novartis 4% 29% +25% Pfizer 17% 24% +7% GSK 8% 24% +16% Otsuka 22% 23% +1% 14
15 Great potential of NEDL market With greater enforcement, NEDL market is believed to offer higher potential in the future, esp. small hospitals in lower tier cities, which have been neglected by MNCs in the past. Current vs. future market size of NEDL drugs (Based on the required revenue ratio of NEDL drugs) 23% 11.2 Bil USD 27% 13.6 Bil USD 35% Tier 1-2 cities 5.0 Bil USD 5.9 Bil USD 12.9 Bil USD 21% 25% 54% Small hospital 50% 25.1 Bil USD 26% 39% Tier 3-4 cities Tier 5 and below cities Current NEDL market Future NEDL market (Est.) Source: MOH Report on pharmaceutical industry operation 2012, IMS China Hospital Pharmacy Audit
16 Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012 NEDL on MNCs Counter actions by MNCs and the impact on MR providers 16
17 MNCs broad market strategies To counter the situation, some MNC drug companies have expanded their footprints into broad markets and smaller hospitals Pfizer Spring Blossom Project Bayer Go West Project In May 2010, Pfizer sponsored a program in collaboration with China International Medical Foundation to provide trainings for doctors from basic health institutions. The project will be carried out over a period of 3 years time, covering 2 million healthcare professionals from rural healthcare centers, CHC, nation wide. 17 Up until June 2011, Bayer s Go West Project has enabled the company to provide professional trainings for 4,000 doctors spanning across 13 provinces in mid-west China. From 2012 to 2017, Bayer is committed to provide more trainings to county doctors, esp. on academic, hospital management, and patient relationship management, etc.
18 More research needs in low tier markets In the past few years, more studies are conducted in smaller cities, esp. tier 5 and below, indicating increased interest and focus on these markets 25,000 No. of samples collected in different tier of cities by IMS Fieldwork in the past 3 years (for primary research only) 20,000 15, ,000 5,000 - Tier 1 cities Tier 2 cities Tier 3-4 cities Tier 5 cities and below 18
19 Measures taken by MNCs Core market Broad market Pricing strategies: - Newly NEDL enlisted products: nationwide pricing adjustment - New products: outlast EDL price cuts before patent expiry Branding: - Differentiate from MNC and local competitions Exploring new patient segments/ indications/ line extensions Bringing in novel products: - Expedite launches of new novel drugs that are less affected by current policy, e.g. rare disease Pricing strategies: - To compete with local players Branding: - Establish brand values - Differentiate from local players Broad market strategy Affordable and innovative services, e.g. video conferencing, web meetings, telemarketing, etc. Generic alliances, M&A, partnership with local distributors 19
20 New challenges facing MR providers 1. More needs for tried and tested techniques in Pricing / value research Brand differentiation New patient segment exploration, etc. 2. Building FW capability in broad markets Continued efforts needed to build FW capability in low tier cities More affordable data capture methods 3. To keep up to date and strengthen knowledge in various therapeutic areas, i.e. rare diseases, etc. 4. Exploring better ways to conduct competitor intelligence studies, to address requests for due diligence, part of M&A requirement. 20
21 Implication of China 2012 NEDL to MNC pharma players Presented by: Li Xingwei Yong Hueyling 21
Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015
Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More informationTABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
More informationSWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY
SWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY KAPIL KUMAR*; DR. M. K. KULSHRESHTHA** *RESEARCH SCHOLAR, BHAGWANT UNIVERSITY, AJMER ** DIRECTOR, S. D. COLLEGE OF MANAGEMENT, PANIPAT ABSTRACT The global
More informationREGULATORY OVERVIEW DISTRIBUTION OF PHARMACEUTICAL PRODUCTS
REGULATORY FRAMEWORK Our products are subject to regulatory controls governing pharmaceutical products and medical appliances and equipment. Thus we are subject to regulation and oversight by different
More informationMultiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013
Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012
More informationChina - One Nation, Multiple Markets
Hong Kong Your Fast Track to China China - One Nation, Multiple Markets Presented by : Fanny Ting Marketing Director Victorinox Hong Kong Limited Agenda 1. How Victorinox Hong Kong (VHK) sees the China
More informationBreast Cancer Drug Discoveries: What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to
More informationChina s 12th Five-Year Plan: Healthcare sector
China s 12th Five-Year Plan: Healthcare sector May 2011 KPMG CHINA One of the guiding principles of the 12th Five-Year Plan (5YP) is inclusive growth : helping ensure that the benefits of the country s
More informationCloud Computing: An enabler of IT in Indian Healthcare Sector. Media Briefing September 29, 2010
Cloud Computing: An enabler of IT in Indian Healthcare Sector Media Briefing September 29, 2010 Executive Summary Indian healthcare spending is about 4.1 percent of its GDP. The Indian healthcare industry
More informationOpportunities in the China Healthcare Sector. December 2008
Opportunities in the China Healthcare Sector December 28 Opportunities in the China Healthcare Sector Executive Summary China s healthcare sector is rapidly developing Total Health expenditure in China
More informationInertial loyalist: Has been satisfied with services received. Does not believe a better offer is available in the marketplace. Renews contract without
PBM Marketing and Sales Practice PBM Marketing & Sales Practice Building a Retention Strategy around Client Loyalty Categories March 2003 Todd Gibson PhD, Director and Practice Leader PBM Marketing and
More informationPharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story
Pharma Lifecycle Management and Brand Defense Strategy Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy 20 July 2014 Terminology
More informationPharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595
Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:
More informationThe Rise of China: Implications for Pharma and Pharma Librarians
The Rise of China: Implications for Pharma and Pharma Librarians Pharmaceutical & Health Technology Division Special Libraries Association March 20, 2012 Essential Insight for the Healthcare Industry Agenda
More informationRetail Pharmacy in South Africa An IMS Perspective. Ruth Deakins Senior Offerings Manager
Retail Pharmacy in South Africa An IMS Perspective Ruth Deakins Senior Offerings Manager Summary Retail pharmacy as a sector is facing a challenging operating environment, however will remain a key channel
More informationSlide 1. Region China overview and strategy. Camilla Sylvest SVP Region China. TEAM NOVO NORDISK Professional cycling team
Slide 1 Region China overview and strategy Camilla Sylvest SVP Region China TEAM NOVO NORDISK Professional cycling team Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished
More informationRegional Inequality in Healthcare in China
Regional Inequality in Healthcare in China QIAN Jiwei* Regional inequality in healthcare in China is particularly wide. Since 2007, the central government has increased earmarked healthcare transfers to
More informationPotential Savings from Generic Drugs in Upstate New York
T H E F A C T S A B O U T Potential Savings from Generic Drugs in Upstate New York $880 Million in Potential Savings for Upstate New York Counties Finger Lakes Region $141 million Western New York Region
More informationChina Pharmaceutical Guide
2013 Volume 1 8th China Pharmaceutical Guide 中 国 医 药 市 场 指 南 8 th Edition (2013) Volume 1 Written by: James J. Shen, MBA Unrivaled China Healthcare Intelligence Since 1991 Copyright 2013 by WiCON International
More informationIndian Agrochemical Industry
Indian Agrochemical Industry Introduction. India is the fourth largest producer of agrochemicals globally, after United States, Japan and China. The agrochemicals industry is a significant industry for
More informationThailand: Analysis of the General Insurance Industry
Brochure More information from http://www.researchandmarkets.com/reports/1958129/ Thailand: Analysis of the General Insurance Industry Description: Despite the political unrest in May 2010 that affected
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationMarket opportunities in China. Summary of market research on China for the early childhood education sector
Market opportunities in China Summary of market research on China for the early childhood education sector Targeted cities in China Seven locations (eight cities) have been selected as the main targets
More informationIMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS
Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. IMPACT OF
More informationCHINA MOBILE LIMITED ANNUAL REPORT 2011. Business Review
20 CHINA MOBILE LIMITED ANNUAL REPORT CHINA MOBILE LIMITED ANNUAL REPORT 21 In, the Group faced increasing penetration and intensifying competition in the traditional telecommunications market. Challenges
More informationVWNMS Dr. Frank Galas 24 th September 2014 Volkswagen Leasing China 1
1 Leasing is the natural choice for commercial customers Fixed low monthly leasing payments full transparency and cost control No bound capital and higher financial freedom for the business Off balance
More informationCommitted to innovation and growth
Committed to innovation and growth Alan Hippe, CFO Roche Group London, September 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by
More informationSucceeding in China. Tom Behrens-Sorensen Navisino (Beijing) Advisors Ltd.
Succeeding in China Tom Behrens-Sorensen Navisino (Beijing) Advisors Ltd. Muligheder og udfordringer 24 millioner SMVer i EU 13% af EU27 SMVer eksporterer uden for det indre marked Kun 250.000 SMVer eksporterer
More informationThe Healthcare market in Brazil
www.pwc.com.br The Healthcare market in Brazil Brazilian Healthcare market: one of the most promising and attractive in the world Context Fifth largest country in area and population, with 8.51 million
More informationSTRATEGY UPDATE 2 MARCH 2016
STRATEGY UPDATE 2 MARCH 2016 Portfolio Focus on Attractive Growth and Margin Opportunities André Lacroix, CEO Intertek Group plc, is today announcing a strategic update outlining the Group s plan to deliver
More informationGroup insurance. Generic drugs. Their positive effect on your wallet
Group insurance Generic drugs Their positive effect on your wallet A wise choice Prescription drugs have a couple of things in common: they re designed to heal us or make us feel better, and most of them
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More informationThe Japan Generic Market Drivers and Obstacles for Change. Matt Heimerdinger Anterio Inc.
The Japan Generic Market Drivers and Obstacles for Change Matt Heimerdinger Anterio Inc. Quick country overview Osaka Tokyo Population: 127,520,000 Life expectancy: Male: 79.9; Female: 86.4 Pharmaceutical
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationHAIER ELECTRONICS GROUP CO., LTD (STOCK CODE: 1169)
To: Business Editor [For immediate release] HAIER ELECTRONICS GROUP CO., LTD (STOCK CODE: 1169) ANNOUNCES INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2012 TURNOVER UP 8.4% TO RMB 26,303,993,000 PROFIT
More informationGCC Pharmaceutical Industry
GCC Pharmaceutical Industry First coordination meeting for the pharmaceutical industry in the GCC and Yemen Dr. Aasim Qureshi 11 April 2011 Global Pharmaceuticals Industry The pharmaceutical industry is
More informationCLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare
CLOSING THE COVERAGE GAP Pan-Canadian Pharmacare Prescription drug coverage for all Canadians While the vast majority of Canadians have access to prescription drugs, some Canadians can t afford their medications.
More informationPfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?
Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Research February 6, 2012 Rusty Jones Companies: Pfizer (PFE) Ranbaxy (OTC: RBXZF) Watson (WPI) Products: Lipitor
More informationParallel Session 2 Five Pillars to succes A framework for approaching market research in Emerging Markets
Parallel Session 2 Five Pillars to succes A framework for approaching market research in Emerging Markets Steve Kretschmer, Ipsos, Turkey and Beyza Ozel, Novartis, Turkey 5 Pillars to Success: A Framework
More informationWyeth Nutrition and Nestlé Nutrition Greater China Region
Wyeth Nutrition and Nestlé Nutrition Greater China Region John Cheung Regional President GCR Wyeth Nutrition James Chiu Regional Business Head GCR Nestlé Infant Nutrition 1 Disclaimer This presentation
More informationBlockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global
Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com
More informationThe Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion
November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,
More informationSaving Money on Prescription Drugs
Reference Guide to Saving Money on Prescriptions Revised: July 11, 2006 Prescription medications can be a heavy financial burden for individuals and families. Many people feel limited to receiving assistance
More informationMalignant Pleural Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,
More informationGlobal Monoclonal Antibodies Pipeline Insight 2015
Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who
More informationMedical Device Reimbursement In China
Medical Device Reimbursement In China Reimbursement has long been an issue of major concern to U.S. pharmaceutical manufacturers trying to sell their products in China. Recent developments have made the
More informationPayer Mix in Oncology
Emerging Markets Market Access & Health Outcomes Oncology Payer Mix in Oncology Understanding cancer payer mix is critical to understanding patient affordability as a component of launch planning Digital
More informationAn Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit
An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit March 2014 PREPARED BY Brenda Motheral, MBA, PhD President Corey Belken, PharmD Vice President Artemetrx Specialty Drug Solutions
More informationOutsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis
Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationDrug Pricing System in Japan
Reference Chuikyo - 1 June 6, 2012 Drug Pricing System in Japan April 2012 (Underlined phrases in red in this text: New features and modifications to the current pricing system adopted by the 2012 system
More informationThe Historical Evolution of China s Drug Regulatory System
The Historical Haona Li 1, He Sun 1,Frances J Richmond 23 1 School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China 2 School of Pharmacy, University of Southern California,
More informationOverview of investment activities of pharmaceutical companies in Russia
Overview of investment activities of pharmaceutical companies in Russia Sponsored by View of foreign pharmaceutical companies on the investment climate in Russia 01 5 View of foreign pharmaceutical companies
More informationMarketsandMarkets. http://www.marketresearch.com/marketsandmarkets-v3719/ Publisher Sample
MarketsandMarkets http://www.marketresearch.com/marketsandmarkets-v3719/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationPharmaceutical Markets in Latin American Countries. Chris Swann Espicom Business Intelligence
Pharmaceutical Markets in Latin American Countries Chris Swann Espicom Business Intelligence Contents Demographics Economic factors Pharmaceutical market characteristics Summary - Overview of markets VENEZUELA
More informationConnecting Business Opportunities in A Better Way
Connecting Business Opportunities in A Better Way Sustainable Growth 250 200 150 100 CAGR: 13% 146.6 182.5 203.9 220 Sales revenue (billion CNY ) 239 13% America 16% Asia Pac 35% China H1: 135.8 Who is
More informationChildren's Hospital Boston - Strategic SWOT Analysis Review
Brochure More information from http://www.researchandmarkets.com/reports/1837823/ Description: Summary Children's Hospital Boston (Children s) is the pediatric medical center that provides a full range
More informationLocation for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014
Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying
More information2011 zamoya.com ltd www.zamoya.com. Nine ways we can help your business use social media.
2011 zamoya.com ltd www.zamoya.com Nine ways we can help your business use social media. social media isn t just for interns The emergence of a powerful new communication platform that reaches well over
More informationThe Industry. Johnson and Johnson is involved in the health care industry. through three distinct business segments: consumer, medical, and
1 Johnson and Johnson Analysis Andrew West and The Industry Johnson and Johnson is involved in the health care industry through three distinct business segments: consumer, medical,
More information2010 Expatriate, Returnee and China Hired Foreigner, Compensation and Benefits Survey
2010 Expatriate, Returnee and China Hired Foreigner, Compensation and Benefits Survey Result Sharing Presentation The American Chamber of Commerce in Shanghai Agenda Study Background Growth Expatriates
More informationSTATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry
Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators
More informationPotential for Apps in Pharmaceutical Development. Steve Hutson Co-founder Virtual PV
Potential for Apps in Pharmaceutical Development Steve Hutson Co-founder Virtual PV Potential for Apps in Pharmaceutical Development Steve Hutson Co-founder Virtual PV Potential for Apps in Pharmaceutical
More informationICRA RESEARCH SERVICES. INDIAN PHARMACEUTICAL INDUSTRY New Pricing Policy: An Update
ICRA RESEARCH SERVICES Corporate Ratings Subrata Ray +91 22 3047 0027 subrata@icraindia. com Shamsher Dewan +91 124 4545 328 shamsherd@icraindia. com INDIAN PHARMACEUTICAL INDUSTRY New Pricing Policy:
More informationComprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED
Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED INVESTOR PRESENTATION NOVEMBER Safe Harbor These slides contain (and the accompanying oral discussion will contain)
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationMost countries will experience an increase in pharmaceutical spending per capita by 2018
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
More informationArticle from: Health Watch. January 2013 Issue 71
Article from: Health Watch January 2013 Issue 71 Similarities between Medicare Prescription Drug Plans and Commercial Exchanges By Shelly S. Brandel and Douglas A. Proebsting The Affordable Care Act (ACA)
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationEnhancing Value With Financial & Operational Excellence
Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive markets
More informationBarco Marketing Case Analysis
Barco Marketing Case Analysis I. Position Statement: Over the past few months, many events have led Barco Projection Systems to be confronted with an important decision: Barco needs to continue its development
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More information[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)]
[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)] Executive Summary Stem Cells have a remarkable ability to develop in various body cells of a human. These occur in the earliest stages
More informationLucintel. http://www.marketresearch.com/lucintel-v2747/ Publisher Sample
Lucintel http://www.marketresearch.com/lucintel-v2747/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays: 5:30am
More informationIntegrated Life Cycle Patient Access Solutions that Maximize Brand ROI
Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI August, 2013 Bob Hastings Vice President of Marketing Pharmaceutical brand marketers are facing a paradigm shift in the way they market
More informationOncology s $5 Billion Opportunity: Oncology Companies Can Improve the Customer Experience
Oncology s $5 Billion Opportunity: Oncology Companies Can Improve the Customer Experience The 2015 ZS Oncology Customer Experience Tracker Jon Roffman, Sankalp Sethi and Pranav Srivastava Oncology s $5
More informationREFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN (POSTMENOPAUSAL VAGINAL ATROPHY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN Executive Summary Premarin (conjugated estrogen cream): Key Metrics in the Seven Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan
More informationJanuary 2016. Price Declines after Branded Medicines Lose Exclusivity in the U.S.
January 2016 Price Declines after Branded Medicines Lose Exclusivity in the U.S. Introduction When novel medicines lose exclusivity in the United States, competitors quickly enter the market and bring
More informationBasic Reimbursement - Medicare Part D Specifics
Basic Reimbursement - Medicare Part D Specifics 60889-R8-V1 (c) 2012 Amgen Inc. All rights reserved 2 This information is provided for your background education and is not intended to serve as guidance
More informationChronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533727/ Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The
More informationCegedim Half-year results 2009 September 2009
Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)32 DAF/COMP/GF/WD(2014)32 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 30-Jan-2014 English
More information3 rd Asia Pacific Pharmaceutical Compliance Congress And Best Practices Forum Sept 10-12 2013, Kuala Lumpur, Malaysia
3 rd Asia Pacific Pharmaceutical Compliance Congress And Best Practices Forum Sept 10-12 2013, Kuala Lumpur, Malaysia Mai Tran COMPLIANCE ISSUES IN SOCIAL MEDIA AND DIGITAL MARKETING Social media landscape
More informationChina s experiences in domestic agricultural support. Tian Weiming China Agricultural University
China s experiences in domestic agricultural support Tian Weiming China Agricultural University Contents Background The policy system Major measures and their implementation Empirical assessment of the
More information5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned
PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We
More informationComparisons of Retail Prices of Generic Prescription Drugs in Canada vs. United States: A Comprehensive Study
Comparisons of Retail Prices of Generic Prescription Drugs in Canada vs. United States: A Comprehensive Study A Report Prepared for the Canadian Generic Pharmaceutical Association By Joseph R. D Cruz Murray
More informationThe Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
More informationThe ADT Corporation. William Blair & Company 2013 Growth Stock Conference JUNE 11, 2013. 2013 ADT LLC dba ADT Security Services. All rights reserved.
The ADT Corporation JUNE 11, 2013 2013 ADT LLC dba ADT Security Services. All rights reserved. William Blair & Company 2013 Growth Stock Conference ADT Overview Leader in life security/life safety/home
More informationHospital Quality Management in the context of Healthcare Reform in China. Yingyao Chen, PhD School of Public Health Fudan University
Hospital Quality Management in the context of Healthcare Reform in China Yingyao Chen, PhD School of Public Health Fudan University April 10-12, 2011 Westlake Forum III Healthcare Reform in China and the
More informationResearch on Competitive Strategies of Telecom Operators in Post-3G Era Based on Industry Chain Value Stream
Research on Competitive Strategies of Telecom Operators in Post-3G Era Based on Industry Chain Value Stream Zhong Wei 1, a, Wang Jianming 2, b and Zhang Yang 3, c 1 Beijing University of Posts and Telecommunications,
More informationMaking Sense of Medicare Advantage and Part D Open Enrollment
Making Sense of Medicare Advantage and Part D Open Enrollment By Stephen L. Cohen, MD Austell, GA About this presentation: We know that a lot of material is presented here. Please go to www.medicaredrugsavings.org
More informationSOCIAL CRM AND ITS IMPACT ON PHARMACEUTICAL INDUSTRY
344 SOCIAL CRM AND ITS IMPACT ON PHARMACEUTICAL INDUSTRY ABSTRACT MR. SHUVAM CHATTERJEE* *Assistant Professor in Marketing, Department of Management Studies, Regent Education & Research Foundation, Barrack
More informationHarmonization of Health Insurance Schemes in China
Harmonization of Health Insurance Schemes in China Hai Fang Professor of Health Economics China Center for Health Development Studies Peking University China Presentation at the First National Conference
More informationChina is getting healthy- What s in for me?
Austria Connect 19.09.2009 China is getting healthy- What s in for me? VAMED Group in China Chronology 1988 1996 Rep. Office Founding in China 33 Hospitals Project MoH 2002 First projects with German Soft
More informationChina s health care reforms
China s health care reforms China wants to establish a basic health system to provide effective, low-cost health services to its more than 1.3 billion citizens. Can it succeed at this ambitious goal? 55
More informationAgFeed Industries, Inc
AgFeed Industries, Inc ( US stock symbol : AGFI ) February 2007 Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Securities
More informationACE: Leader in the European Automotive Components Market
ACE: Leader in the European Automotive Components Market ACE 2012-2015 Strategy 21/12/2011 Following on from our Current Report in December 2010, ACE s management herein presents its 2011 update on the
More information